SEC Comment Letter 0000000000-23-003563 to BIOMARIN PHARMACEUTICAL INC (BMRN)

BIOMARIN PHARMACEUTICAL INC
Date: April 10, 2023 · CIK: 0001048477 · Accession: 0000000000-23-003563

View on Edgar

AI Filing Summary & Sentiment

Sentiment

Urgency

Document Type

Confidence

SEC Posture

Company Posture

Summary

Reasoning

File numbers found in text: 000-26727

Date

April 10, 2023

Author

Brian R. Mueller

Form

UPLOAD

Company

BIOMARIN PHARMACEUTICAL INC

Letter

United States securities and exchange commission logo April 10, 2023 Brian R. Mueller Executive Vice President, Finance & Chief Financial Officer BioMarin Pharmaceutical Inc. 770 Lindaro Street San Rafael, CA 94901 Re:BioMarin Pharmaceutical Inc. Form 10-K for the Year Ended December 31, 2022 Filed February 27, 2023 File No. 000-26727 Dear Brian R. Mueller: We have completed our review of your filing. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Sincerely, Division of Corporation Finance Office of Life Sciences

Show Raw Text

United States securities and exchange commission logo
April 10, 2023
Brian R. Mueller
Executive Vice President, Finance & Chief Financial Officer
BioMarin Pharmaceutical Inc.
770 Lindaro Street
San Rafael, CA 94901
Re:BioMarin Pharmaceutical Inc.
Form 10-K for the Year Ended December 31, 2022
Filed February 27, 2023
File No. 000-26727
Dear Brian R. Mueller:
            We have completed our review of your filing.  We remind you that the company and its
management are responsible for the accuracy and adequacy of their disclosures, notwithstanding
any review, comments, action or absence of action by the staff.
Sincerely,
Division of Corporation Finance
Office of Life Sciences

SecProbe.io